A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
Stellate Ganglion Blockade for the Prevention of Atrial Fibrillation After Cardiac Surgery: A Randomized Placebo-Controlled Trial
Sponsor: Mayo Clinic
Listed as NCT05357690, this PHASE2/PHASE3 trial focuses on Atrial Fibrillation and remains actively recruiting participants. Sponsored by Mayo Clinic, it has been updated 10 times since 2023, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 5 earlier versions
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Feb 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Sep 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .